Ronald Jeffery Hilton
Ron Hilton, Co-founding partner of ÉlpisÉremo, and Cofounder & Chairman of the board of R&N Hilton Enterprises, CLUB R&N HILTON, and RJ HILTON LIVING. Ron is the Grandson of Conrad N Hilton and the son of Barron Hilton, an American business magnate, socialite, and hotel heir, much like his grandfather and father - a founding partner of the American Football League and the original owner of the Los Angeles Chargers., Ron embodies the HILTON American business magnate entrepreneurial and philanthropy spirit, and helped established ÉlpisÉremo with world leading scientific experts to accelerate cutting edge biotechnology for patients who are suffering from devastating degenerative and debilitating diseases for which no cure or treatment. He has deep knowledge and experience from working at Hilton. Currently Ron is involved in RJ Hilton Marketing focuses on International Real Estate Development and Music Management, Hospitality.
Ronald Jeffery Hilton
Ron Hilton, Co-founding partner of ÉlpisÉremo, and Cofounder & Chairman of the board of R&N Hilton Enterprises, CLUB R&N HILTON, and RJ HILTON LIVING. Ron is the Grandson of Conrad N Hilton and the son of Barron Hilton, an American business magnate, socialite, and hotel heir, much like his grandfather and father - a founding partner of the American Football League and the original owner of the Los Angeles Chargers., Ron embodies the HILTON American business magnate entrepreneurial and philanthropy spirit, and helped established ÉlpisÉremo with world leading scientific experts to accelerate cutting edge biotechnology for patients who are suffering from devastating degenerative and debilitating diseases for which no cure or treatment. He has deep knowledge and experience from working at Hilton. Currently Ron is involved in RJ Hilton Marketing focuses on International Real Estate Development and Music Management, Hospitality.
Severe Heart Failure Center
It is a treatment for patients with severe heart failure who cannot find a donor.
It is a treatment for patients with severe heart failure who cannot find a donor.
HEART GNESIS, which develops next-generation heart treatment technology, succeeded in extending the survival period of patients by more than 10 years after successfully transplanting [eHL-1] to patients who were waiting for death because a donor could not be found.
Currently, the length of life extension for patients is being updated on a daily basis.
[eHL-1] cell line is designed to regenerate and restore heart function in patients with severe heart failure.
The following video shows echo images before and after transplant treatment of a patient who was successfully transplanted with a surgical fetal stem cell line [eHL-1] to a patient with severe heart failure for whom a donor could not be found.
[eHL-1] The patient's heart is clearly abnormal before transplant treatment.
However, you will understand that after transplant treatment, the patient's heart completely eliminates abnormalities, regenerates into a healthy heart, and even returns to a young heart.
What is Severe Heart Failure？
Severe heart failure is a condition in which the heart is not able to pump enough blood throughout the body for its normal function. The cause of this can be either functional or structural disorder of the heart. Common causes of severe heart failure include cardiomyopathy, hypertension, heart valve problems and coronary artery disease. There is no cure for Severe Heart Failure.
Can stem cells help treat heart failure?
With respect to the heart, stem cells have the ability to not only home into the damaged areas but also to initiate a cascade of biological events which both culminate in healing of the heart muscle. So far, the world has succeeded in treating heart failure stem cells.However, it has not been successful in treating patients in need of donors with severe heart failure.Heart Genesis is the first in the world to successfully treat patients with severe heart failure with stem cells.
SEVERE HEART FAILURE
It is said that there are 100,000 patients who need heart transplants worldwide, but only 3,500 have actually received heart transplants.
Type of Treatment
Heart Transplant
Heart transplant: At Armadyne Regeneration Center, we have a team of the best heart specialists in world who specialize in treating heart failure through a heart transplant. When all other approaches fail to improve the symptoms, the doctor may suggest replacement of weakened heart with a healthy heart from a matching donor.
Stem Cell Therapy
The Armadyne Regenerate Center has the world's first successful cardiac surgery team to treat heart disease with stem cells and the world's first cardiac surgery team to cure severe heart failure with stem cells.
Stem Cell Therapy
Stem Cell Treatment:
Severe Heart Failure Protocols
Treatment protocol will be assigned by staff physicians after the patient has submitted all requested medical information and received approval. A patient’s recommended protocol may differ from the example given below.
1. Treatment duration: 7 days and 8 nights～
2. Physical examination and blood testing: Monday.
3 IV injections of stem cells.
4. There are two types of protocols IV and surgery.
By transplanting the fetal stem cell line [eHL-1], patients who are waiting for a heart donor or who cannot find a heart donor will be able to find a new avenue of hope through [eHL-1] transplant treatment.
These results are predicted to become the main treatment method for patients with severe heart failure in the future.
In other words, our fetal stem cell line [eHL-1] is predicted to create a world without the need for heart donors in a few years.
The Problem of Severe Heart Failure (Patients on Donor Waiting List)
Patients in need of urgent care (patients on donor waiting list and patients with artificial hearts) present significant problems.
Patients on donor waiting list
Serious problem
-
Many patients die because they cannot find a donor.
-
When donating organs, heart donation to elderly people is said to be impossible because the criteria for indication for organ donation states that hearts should be 50 years old or younger.
-
In other words, patients over the age of 50 have no choice but to be fitted with an artificial heart or wait for death.
Serious problem
Serious problem
-
The survival rate after implantable ventricular assist device surgery is 95% at 1 year, but the average length of support is short at 2 ± 1.2 years, with the current maximum being 5.4 years.
-
The patient will be placed on an artificial heart until a donor is found. However, many patients die because a donor cannot be found.
Benefits of having Cardiac Cell Therapy
Sustained improvement in heart pumping power and its ability to regulate proper supply blood to the body
Improved regulation of O2 (Oxygen) Intake and Use.
Increase in myocardial performance, neurohumoral activations, and functional heart capacity
Greater Reduction in Angina Reduction in the infarct size with a reduction in heart muscle scar and reversal of cardiogenic shock
Long-term follow-up (≥5 years) shows noticeable improvement in the patients overall well-being and physical endurance.
